John N. Allan, MD | Authors


Pooled Analysis of Ibrutinib Shows Long-Term Efficacy in CLL

May 05, 2021

John N. Allan, MD, discusses a pooled analysis of 4 clinical trials with 4-year follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia and TP53 aberration deletion 17p or a TP53 mutation.